Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

$651 Million Aptamers Market Assessment and Outlook, 2032 | Chemical Engineering, Targeted Delivery, and AI-Assisted Discovery are Major Growth Catalysts

globenewswire.com
AGNC Agilent Technologies is mentioned as a company within the aptamers market. The article provides a general market outlook and does not offer specific sentiment towards Agilent. BIIB While not explicitly mentioned, Biogen is a major player in the biotech sector and could be indirectly impacted by advancements in aptamer technology, which is a key growth area in therapeutics. REGN Regeneron Pharmaceuticals is a significant biotechnology company that could be involved in or affected by the aptamers market, particularly in therapeutic applications like ophthalmology. ALNY Alnylam Pharmaceuticals, a leader in RNAi therapeutics, operates in a related field to aptamers, suggesting potential synergies or competition within the broader therapeutic development landscape. CRSP CRISPR Therapeutics is at the forefront of gene editing, a field that intersects with aptamer technology in therapeutic development, indicating potential relevance and impact. GILD Gilead Sciences is a major biopharmaceutical company with interests in various therapeutic areas, including oncology and infectious diseases, where aptamers are being explored. AMGN Amgen Inc. is a large biotechnology company involved in developing therapies for serious illnesses, a sector where aptamer technology is showing promise for novel drug development. BMY Bristol Myers Squibb is a global biopharmaceutical company with a broad portfolio, including oncology and immunology, areas where aptamer-based therapeutics are being investigated. MRK Merck & Co. is a major pharmaceutical company with significant research and development in oncology and other therapeutic areas where aptamer technology could play a role. PFE Pfizer Inc. is a global pharmaceutical giant with diverse R&D efforts, including in oncology and immunology, fields where aptamer applications are being explored for novel treatments. JNJ Johnson & Johnson, through its pharmaceutical segment, is involved in developing treatments for various diseases, including cancer and autoimmune disorders, where aptamer technology is relevant. ABBV AbbVie Inc. focuses on immunology, oncology, and neuroscience, therapeutic areas where aptamer-based therapies are being investigated for improved treatment outcomes. LLY Eli Lilly and Company is a major pharmaceutical firm with research in areas like oncology, immunology, and neuroscience, where aptamer technology presents potential therapeutic advancements. AZN AstraZeneca PLC is a global biopharmaceutical company with strong research in oncology, cardiovascular, and respiratory diseases, areas where aptamer technology is being explored. NVS Novartis AG is a leading pharmaceutical company with a focus on innovative medicines, including in oncology and ophthalmology, where aptamer technology is relevant for targeted therapies. SNY Sanofi S.A. is a global healthcare company with a broad therapeutic focus, including oncology and immunology, where aptamer technology is being explored for novel treatment modalities. TEVA Teva Pharmaceutical Industries Ltd. is a global leader in generics and specialty medicines, potentially impacted by advancements in aptamer technology for novel drug development. BSX Boston Scientific Corporation is a medical device company that could benefit from or be impacted by aptamer technology, particularly in areas like targeted drug delivery and diagnostics. MDLZ Mondelez International is a global food and beverage company. While not directly related to aptamers, the article mentions food safety testing as an application area for aptamers. GOOG Alphabet Inc. (Google) is heavily involved in AI and machine learning, which are identified as major growth catalysts for the aptamers market, suggesting potential indirect impact. MSFT Microsoft Corporation's significant investments in AI and cloud computing align with the article's emphasis on AI-assisted discovery as a key driver for the aptamers market. IBM IBM's focus on AI and data analytics is relevant to the article's discussion of AI-assisted discovery as a major growth catalyst in the aptamers market. NVDA NVIDIA Corporation's leading position in AI hardware is crucial for the computational power needed for AI-assisted discovery, a key driver mentioned for the aptamers market. INTC Intel Corporation's role in providing computing infrastructure is relevant to the growth of AI-assisted discovery, a significant catalyst for the aptamers market. AMD Advanced Micro Devices, Inc. (AMD) is a key player in the semiconductor industry, providing processors essential for the AI and machine learning computations driving aptamer discovery. QCOM Qualcomm Incorporated's involvement in mobile and AI technologies could indirectly support the infrastructure for AI-assisted discovery in the aptamers market. AMZN Amazon.com, Inc. (AWS) provides cloud computing services essential for AI and machine learning, which are highlighted as major growth drivers for the aptamers market. CRM Salesforce, Inc. offers cloud-based software, including AI tools, which can support data analysis and collaboration in research and development, relevant to the aptamers market. ORCL Oracle Corporation provides enterprise software and cloud services that can be utilized for managing and analyzing complex biological data in R&D, including aptamer research. SAP SAP SE's enterprise software solutions can support the operational and data management needs of companies involved in aptamer research and development. ADBE Adobe Inc. provides software for content creation and digital experiences, which can be used for visualizing and communicating research findings in the aptamers field. GOOGL Alphabet Inc. (Google) is heavily involved in AI and machine learning, which are identified as major growth catalysts for the aptamers market, suggesting potential indirect impact. META Meta Platforms, Inc. is investing in AI research and development, which is a key driver for the aptamers market as described in the article. NFLX Netflix, Inc. is not directly related to the aptamers market or AI advancements mentioned in the article. DIS The Walt Disney Company is not directly related to the aptamers market or AI advancements mentioned in the article. CMCSA Comcast Corporation is not directly related to the aptamers market or AI advancements mentioned in the article. VZ Verizon Communications Inc. is not directly related to the aptamers market or AI advancements mentioned in the article. T AT&T Inc. is not directly related to the aptamers market or AI advancements mentioned in the article. XOM Exxon Mobil Corporation is an energy company and not directly related to the aptamers market or AI advancements mentioned in the article. CVX Chevron Corporation is an energy company and not directly related to the aptamers market or AI advancements mentioned in the article. KO The Coca-Cola Company is a beverage company and not directly related to the aptamers market or AI advancements mentioned in the article. PEP PepsiCo, Inc. is a food and beverage company and not directly related to the aptamers market or AI advancements mentioned in the article. MCD McDonald's Corporation is a fast-food company and not directly related to the aptamers market or AI advancements mentioned in the article. SBUX Starbucks Corporation is a coffeehouse chain and not directly related to the aptamers market or AI advancements mentioned in the article. COST Costco Wholesale Corporation is a retail company and not directly related to the aptamers market or AI advancements mentioned in the article. WMT Walmart Inc. is a retail company and not directly related to the aptamers market or AI advancements mentioned in the article. BABA Alibaba Group Holding Limited is a Chinese multinational technology company. While it has AI initiatives, its primary listing is not on a US exchange, and its direct relevance to the aptamers market is not detailed. JD JD.com, Inc. is a Chinese e-commerce company. While it may have AI applications, its primary listing is not on a US exchange, and its direct relevance to the aptamers market is not detailed. BIDU Baidu, Inc. is a Chinese technology company heavily invested in AI. While AI is a key driver for the aptamers market, Baidu's primary listing is not on a US exchange. NTES NetEase, Inc. is a Chinese internet technology company. Its direct relevance to the aptamers market or AI advancements mentioned in the article is not detailed, and its primary listing is not on a US exchange. PDD Pinduoduo Inc. is a Chinese e-commerce company. Its direct relevance to the aptamers market or AI advancements mentioned in the article is not detailed, and its primary listing is not on a US exchange. SIRI Sirius XM Holdings Inc. is a media company and not directly related to the aptamers market or AI advancements mentioned in the article. AMC AMC Entertainment Holdings, Inc. is an entertainment company and not directly related to the aptamers market or AI advancements mentioned in the article. GME GameStop Corp. is a retail company and not directly related to the aptamers market or AI advancements mentioned in the article. TSLA Tesla, Inc. is an electric vehicle and clean energy company. While it uses AI, it's not directly related to the aptamers market discussed in the article. NIO NIO Inc. is an electric vehicle manufacturer. While it uses AI, it's not directly related to the aptamers market discussed in the article. RIVN Rivian Automotive, Inc. is an electric vehicle manufacturer. While it uses AI, it's not directly related to the aptamers market discussed in the article. LCID Lucid Group, Inc. is an electric vehicle manufacturer. While it uses AI, it's not directly related to the aptamers market discussed in the article. F Ford Motor Company is an automotive manufacturer. While it is investing in EVs and AI, it's not directly related to the aptamers market discussed in the article. GM General Motors Company is an automotive manufacturer. While it is investing in EVs and AI, it's not directly related to the aptamers market discussed in the article. STLA Stellantis N.V. is an automotive manufacturer. While it is investing in EVs and AI, it's not directly related to the aptamers market discussed in the article. TM Toyota Motor Corporation is an automotive manufacturer. While it is investing in EVs and AI, it's not directly related to the aptamers market discussed in the article. HON Honeywell International Inc. is a diversified technology and manufacturing company. Its involvement in areas like advanced materials and building technologies could indirectly intersect with the aptamers market. GE General Electric Company is involved in aerospace, healthcare, and power. Its healthcare division could be indirectly related to aptamer applications in diagnostics or therapeutics. BA The Boeing Company is an aerospace company and not directly related to the aptamers market or AI advancements mentioned in the article. LMT Lockheed Martin Corporation is a defense contractor. Its involvement in biodefense and rapid diagnostics mentioned in the article could have indirect links to aptamer applications. RTX Raytheon Technologies Corporation is a defense contractor. Its involvement in areas like sensing and intelligence could have indirect links to aptamer applications. GD General Dynamics Corporation is a defense contractor. Its direct relevance to the aptamers market or AI advancements mentioned in the article is not detailed. CAT Caterpillar Inc. is an industrial company and not directly related to the aptamers market or AI advancements mentioned in the article. DE Deere & Company is an agricultural and construction equipment company and not directly related to the aptamers market or AI advancements mentioned in the article. MMM 3M Company is a diversified technology company. Its materials science expertise could indirectly relate to aptamer development, but no direct mention is made. DOW Dow Inc. is a materials science company. Its products could be used in the manufacturing of aptamers, but no direct mention is made. DD DuPont de Nemours, Inc. is a materials science company. Its products could be used in the manufacturing of aptamers, but no direct mention is made. LULU Lululemon Athletica Inc. is an apparel company and not directly related to the aptamers market or AI advancements mentioned in the article. NKE NIKE, Inc. is an apparel and footwear company and not directly related to the aptamers market or AI advancements mentioned in the article. HD The Home Depot, Inc. is a retail company and not directly related to the aptamers market or AI advancements mentioned in the article. LOW Lowe's Companies, Inc. is a retail company and not directly related to the aptamers market or AI advancements mentioned in the article. SPG Simon Property Group, Inc. is a real estate company and not directly related to the aptamers market or AI advancements mentioned in the article. PLD Prologis, Inc. is a real estate company and not directly related to the aptamers market or AI advancements mentioned in the article. AMT American Tower Corporation is a real estate investment trust and not directly related to the aptamers market or AI advancements mentioned in the article. EQIX Equinix, Inc. provides data center infrastructure. Its services are crucial for AI and data processing, which are key drivers for the aptamers market. PLTR Palantir Technologies Inc. specializes in big data analytics and AI platforms, which are highly relevant to the AI-assisted discovery aspect of the aptamers market. SNOW Snowflake Inc. provides a cloud-based data warehousing platform, essential for managing and analyzing the large datasets used in AI-driven research, including aptamer discovery. DDOG Datadog, Inc. offers monitoring and analytics for cloud applications, which can be vital for managing the complex computational infrastructure supporting AI in aptamer research. CRWD CrowdStrike Holdings, Inc. provides cloud security solutions. While not directly related to aptamers, its focus on AI-driven cybersecurity is in a related tech sector. PANW Palo Alto Networks, Inc. is a cybersecurity company utilizing AI. Its relevance is indirect, related to the broader AI trend driving the aptamers market. ZS Zscaler, Inc. provides cloud security solutions. Its relevance is indirect, related to the broader AI trend driving the aptamers market. FTNT Fortinet, Inc. provides cybersecurity solutions. Its relevance is indirect, related to the broader AI trend driving the aptamers market. VRTX Vertex Pharmaceuticals Incorporated is a leading biotech company focused on developing transformative medicines. Its work in areas like genetic disorders could intersect with aptamer applications.

$651 Million Aptamers Market Assessment and Outlook, 2032 | Chemical Engineering, Targeted Delivery, and AI-Assisted Discovery are Major Growth Catalysts Dublin, Sept. 10, 2026 (GLOBE NEWSWIRE) -- "Aptamers Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.

The global aptamers market research report examines a sector projected to reach USD 320.74 million in 2026 and grow at a CAGR of 12.51% to USD 651.63 million by 2032. It evaluates clinical validation, technological advances, artificial intelligence applications, regional dynamics, and commercialization opportunities to support strategic planning and market entry decisions.

Regulatory precedent reinforces the commercial opportunity. The U.S. FDA approved pegaptanib for neovascular age-related macular degeneration in 2004 and avacincaptad pegol for geographic atrophy in 2023, demonstrating that well-designed aptamers can satisfy clinical, manufacturing, and regulatory requirements.

Transformative Shifts in Aptamer Therapeutics

The market is progressing from research-use binders toward clinically engineered modalities. Technologies including 2-fluoro, 2-O-methyl, locked nucleic acid chemistry, polyethylene glycol conjugation, and nuclease-resistant backbones are improving stability, half-life, and pharmacokinetic control.

Aptamer-drug conjugates, aptamer-siRNA constructs, and cell-specific targeting systems are also being investigated to improve therapeutic index in oncology, immunology, ophthalmology, and coagulation disorders. Compact size, synthetic manufacturing, low batch variability, and reversible binding may provide strategic advantages over antibodies in selected applications.

Impact of Artificial Intelligence

Machine learning can analyze enriched SELEX pools, identify sequence motifs, predict secondary structures, and prioritize candidates before wet-lab validation. AI also supports assessments of off-target risk, nuclease sensitivity, folding behavior, sequence diversity, and conjugation feasibility.

The greatest value comes from combining computational design with iterative selection, biophysical validation, and translational pharmacology. These insights enable decision-makers to evaluate discovery partnerships, prioritize technology investments, and reduce development risk.

Regional and Economic Group Insights

North America remains a leading market due to FDA precedent, NIH-supported research, private capital, and mature biotechnology infrastructure. Europe benefits from oligonucleotide expertise, advanced biomanufacturing, coordinated regulation, and strong clinical research across Germany, France, the United Kingdom, Italy, and Spain.

Asia-Pacific is gaining momentum through expanding clinical trial capacity, biotechnology investment, large patient populations, and strong nucleic acid research in China, Japan, South Korea, India, Australia, and ASEAN markets. Latin America is advancing through biomedical partnerships and clinical studies, while the Middle East is investing in genomics and specialty care. Africa remains earlier stage, with opportunities linked to diagnostics, infectious disease research, and academic collaboration.

ASEAN offers growing demand for affordable precision diagnostics. The GCC is creating pathways for high-value applications through healthcare modernization, while the European Union provides harmonized clinical trial regulation and public research funding.

BRICS markets contribute patient diversity, scientific output, and manufacturing capacity. G7 countries influence evidence, intellectual property, reimbursement, pharmacovigilance, and quality standards. NATO countries are relevant to biodefense, rapid diagnostics, emergency preparedness, and resilient medical supply chains.

Country-Level Opportunities

The United States leads commercialization, supported by approved products, specialist clinical networks, and venture-backed biotechnology. Canada is strong in genomics and nanomedicine, while Brazil and Mexico offer expanding clinical research networks.

China combines academic output with manufacturing scale. India offers cost-efficient development and pharmaceutical capabilities. Japan and South Korea provide advanced diagnostics and rigorous regulatory systems, while Australia is a recognized early-phase clinical trial hub. Country-level comparisons support market prioritization, partnership selection, and risk-aware expansion strategies.

Strategic Recommendations

Industry leaders should prioritize targets where aptamers offer clear differentiation, including extracellular proteins, localized ocular targets, cell-surface receptors, and applications requiring rapid optimization, synthetic scalability, or reversible binding.

Early investment should address nuclease stability, immunogenicity, analytical characterization, delivery, and chemistry, manufacturing, and controls comparability. Partnerships with AI discovery companies, oligonucleotide manufacturers, academic laboratories, and clinical investigators can accelerate development, provided computational findings are confirmed through binding kinetics, functional assays, structural analysis, and clinically relevant models.

Key Takeaways from This Report

Key Attributes

Key Topics Covered

1. Preface

1.1. Objectives of the Study

1.2. Market Definition

1.3. Market Segmentation & Coverage

1.4. Years Considered for the Study

1.5. Currency Considered for the Study

1.6. Language Considered for the Study

1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction

2.2. Research Design

2.2.1. Primary Research

2.2.2. Secondary Research

2.3. Research Framework

2.3.1. Qualitative Analysis

2.3.2. Quantitative Analysis

2.4. Market Size Estimation

2.4.1. Top-Down Approach

2.4.2. Bottom-Up Approach

2.5. Data Triangulation

2.6. Research Outcomes

2.7. Research Assumptions

2.8. Research Limitations

3. Executive Summary

3.1. Introduction

3.2. CXO Perspective

3.3. New Revenue Opportunities

3.4. Next-Generation Business Models

3.5. Industry Roadmap

4. Market Overview

4.1. Introduction

4.2. Industry Ecosystem & Value Chain Analysis

4.2.1. Supply-Side Analysis

4.2.2. Demand-Side Analysis

4.2.3. Stakeholder Analysis

4.3. Market Dynamics

4.3.1. Key Drivers

4.3.2. Key Restraints

4.3.3. Key Opportunities

4.3.4. Key Challenges

4.4. Porter's Five Forces Analysis

4.5. PESTLE Analysis

4.6. Market Outlook

4.6.1. Near-Term Market Outlook (0-2 Years)

4.6.2. Medium-Term Market Outlook (3-5 Years)

4.6.3. Long-Term Market Outlook (5-10 Years)

4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective

5.2. Consumer Experience Benchmarking

5.3. Opportunity Mapping

5.4. Distribution Channel Analysis

5.5. Pricing Trend Analysis

5.6. Regulatory Compliance & Standards Framework

5.7. ESG & Sustainability Analysis

5.8. Disruption & Risk Scenarios

5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Aptamers Market, by Type

7.1. Introduction

7.2. Nucleic Acid Aptamers

7.2.1. DNA Aptamers

7.2.2. RNA Aptamers

7.3. Peptide Aptamers

8. Aptamers Market, by Technology

8.1. Introduction

8.2. Non-SELEX-Based Technologies

8.3. SELEX Technology

8.3.1. Capillary Electrophoresis (CE)-SELEX

8.3.2. Capture-SELEX

8.3.3. Cell-SELEX

8.3.4. Graphene Oxide (GO)-SELEX

8.3.5. Microfluidic SELEX

8.3.6. Standard SELEX

9. Aptamers Market, by Application

9.1. Introduction

9.2. Clinical Diagnostics

9.2.1. Cardiovascular & Metabolic Disease Diagnostics

9.2.2. Genetic & Rare Disease Screening

9.2.3. Infectious Disease Diagnostics

9.2.4. Neurological Disorder Diagnostics

9.2.5. Oncology Diagnostics

9.3. Food & Environmental Safety

9.3.1. Agricultural Testing

9.3.2. Environmental Monitoring

9.3.3. Food Safety Testing

9.4. Therapeutics & Drug Development

9.4.1. Cardiovascular Diseases

9.4.2. Infectious Diseases

9.4.3. Neurological Disorders

9.4.4. Oncology

9.4.5. Rare & Genetic Disorders

10. Aptamers Market, by End-User

10.1. Introduction

10.2. Academic & Research Institutions

10.3. Hospital & Clinics

10.4. Pharmaceutical & Biotechnology Companies

11. Aptamers Market, by Region

11.1. Introduction

11.2. Asia-Pacific

11.3. Europe

11.4. North America

11.5. Latin America

11.6. Africa

11.7. Middle East

12. Aptamers Market, by Group

12.1. Introduction

12.2. NATO

12.3. G7

12.4. BRICS

12.5. European Union

12.6. ASEAN

12.7. GCC

13. Aptamers Market, by Country

13.1. Introduction

13.2. China

13.3. United States

13.4. Japan

13.5. India

13.6. Germany

13.7. United Kingdom

13.8. Australia

13.9. France

13.10. South Korea

13.11. Italy

13.12. Canada

13.13. Russia

13.14. Brazil

13.15. Mexico

13.16. Spain

14. Competitive Landscape

14.1. Market Share Analysis, 2025

14.2. Market Concentration Analysis, 2025

14.2.1. Concentration Ratio (CR)

14.2.2. Herfindahl Hirschman Index (HHI)

14.3. Recent Developments & Impact Analysis, 2025

14.4. Product Portfolio Analysis, 2025

14.5. Benchmarking Analysis, 2025

15. Company Profiles

15.1. 2bind GmbH

15.2. Agilent Technologies, Inc.

15.3. Aptadel Therapeutics SL

15.4. Aptagen, LLC

15.5. AptaMatrix, Inc.

15.6. Aptamer Group PLC

15.7. AptaTargets SL

15.8. AptusBiotech

15.9. Astellas Pharma Inc.

15.10. Base Pair Biotechnologies, Inc.

15.11. Basking Biosciences

15.12. Bio-Techne Corporation

15.13. Biogenes Technologies Sdn. Bhd.

15.14. Biotage

15.15. Cage Bio, Inc.

15.16. Creative Biogene

15.17. Creative Biolabs

15.18. Drive Therapeutics, LLC

15.19. F. Hoffmann-La Roche AG

15.20. Kaneka Eurogentec S.A.

15.21. NEC Corporation

15.22. NeoVentures Biotechnology Inc.

15.23. NOVAPTECH, S.A.S.

15.24. Profacgen

15.25. SomaLogic, Inc.

15.26. TAGCyx Biotechnologies, Inc.

15.27. Veraptus

15.28. Vivonics Inc.

15.29. Zentek Ltd.

16. Key Experts

For more information about this report visit https://www.researchandmarkets.com/r/t9r7k8

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.